# Abeona Therapeutics Inc. (ABEO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $354M  
**Price:** $5.36 (-1.65%)

> Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious genetic and rare diseases. Headquartered in Cleveland, Ohio, and founded in 1974, the company concentrates on advanced platforms such as adeno-associated virus (AAV) gene therapies and cell-based approaches targeting conditions with high unmet medical need. Abeona Therapeutics’ pipeline is oriented toward disorders where durable treatment effects from a single administration could transform patient outcomes, particularly in inherited metabolic and connective tissue diseases. Its work spans research, clinical development, and regulatory interactions to bring novel therapies through late-stage trials. Within the healthcare technology and pharmaceutical sectors, Abeona Therapeutics plays a specialized role at the intersection of gene therapy innovation and rare disease medicine, collaborating with academic centers, clinical investigators, and industry partners to advance its therapeutic candidates and support broader adoption of gene-based treatments in modern medicine.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6M | — | -$89M | $71M | — |
| 2023 | $4M | — | -$47M | -$54M | — |
| 2022 | $1M | — | -$51M | -$40M | — |
| 2021 | $3M | — | -$90M | -$85M | — |
| 2020 | $10M | — | -$81M | -$84M | — |
| 2018 | $3M | — | -$58M | -$57M | — |
| 2017 | $837,000 | — | -$28M | -$27M | — |
| 2016 | $889,000 | — | -$24M | -$22M | — |
| 2015 | $1M | — | -$19M | -$15M | — |
| 2014 | $925,000 | — | -$3M | -$27M | — |
| 2013 | $2M | — | -$4M | $4M | — |
| 2012 | $4M | — | -$4M | -$11M | — |
| 2011 | $2M | — | -$8M | -$3M | — |
| 2010 | $481,000 | — | -$8M | -$8M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $220M | $60M | $159M | $78M | $20M |
| 2023 | $64M | $49M | $15M | $14M | — |
| 2022 | $64M | $37M | $27M | $14M | — |
| 2021 | $80M | $37M | $42M | $33M | — |
| 2020 | $151M | $49M | $103M | $13M | — |
| 2018 | $174M | $40M | $134M | $19M | — |
| 2017 | $179M | $9M | $170M | $138M | — |
| 2016 | $111M | $12M | $99M | $69M | — |
| 2015 | $80M | $12M | $68M | $40M | — |
| 2014 | $17M | $12M | $5M | $12M | — |
| 2013 | $613,000 | $15M | -$15M | $424,000 | — |
| 2012 | $2M | $19M | -$17M | $396,000 | — |
| 2011 | $4M | $21M | -$18M | $2M | — |
| 2010 | $9M | $30M | -$21M | $7M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$76M | $8M | -$84M |
| 2024 | -$56M | $2M | -$58M |
| 2023 | -$37M | $331,000 | -$37M |
| 2022 | -$43M | $130,000 | -$44M |
| 2021 | -$66M | $4M | -$70M |
| 2020 | -$35M | $1M | -$36M |
| 2019 | -$63M | $6M | -$69M |
| 2018 | -$39M | $9M | -$48M |
| 2017 | -$23M | $860,000 | -$24M |
| 2016 | -$13M | $519,000 | -$14M |
| 2013 | $1,000 | $2,000 | -$1,000 |
| 2012 | -$4M | $13,000 | -$4M |
| 2011 | -$8M | $40,000 | -$8M |
| 2010 | -$7M | $7,000 | -$7M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ABEO)